FDA Approval of RSV Drug Gives Infants and Toddlers Long-Lasting Protection – MedCity News
AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.